A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Small Cell Lung Cancer
Age: Between 18 - 100 Years
Gender: Male or Female
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patient should not have received more than 1 prior line of chemotherapy (could have received immunotherapy which does not count as chemotherapy).
- Male and female subjects of child- bearing potential must agree to use a double-barrier method of birth control from the screening visit through 3 months after the last dose of study drug.
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required